Prednisolone Tebutate

Summary

Prednisolone Tebutate (CHEMBL1200909) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 458.6 Da · C27H38O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200909
Name	Prednisolone Tebutate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	93055
Molecular formula	C27H38O6
Molecular weight	458.6
InChIKey	HUMXXHTVHHLNRO-KAJVQRHHSA-N

SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CC(C)(C)C)O)CCC4=CC(=O)C=C[C@]34C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 3,3-dimethylbutanoate

Also known as: Anhydrous prednisolone tebutate, Hydeltra-tba, Prednisolone butylacetate, Prednisolone tebutate, PREDNISOLONE TEBUTATE, SID170465430

Patent coverage: 938 distinct patent families (3,639 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).